OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis $42.03 0.00 (0.00%) As of 10/13/2026 03:38 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendNews and Trends About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$42.03▼$42.2250-Day Range$41.31▼$46.2152-Week Range$31.80▼$49.31Volume349 shsAverage Volume1,255 shsMarket CapitalizationN/AP/E Ratio13.58Dividend Yield0.76%Price TargetN/AConsensus RatingN/A Company Overview Hikma Pharmaceuticals PLC is a global pharmaceutical company headquartered in London, United Kingdom. Founded in 1978 by Samih Darwazah in Jordan, the company develops, manufactures and markets a broad range of prescription medicines for healthcare providers and patients. Hikma operates through three principal businesses: Injectables, Generics and Branded Medicines. Its portfolio includes hospital injectable products, specialty and generic medicines, and branded pharmaceutical products in areas such as respiratory care, cardiovascular treatment, pain management, anti-infectives and central nervous system therapies. The company also provides ready-to-use and other specialized injectable formulations for hospitals and healthcare professionals. The company serves markets across North America, the Middle East and North Africa, and Europe, with manufacturing, research and commercial operations in multiple countries. Hikma’s leadership is headed by Chief Executive Officer Siggi Olafsson, who became CEO in 2023.AI Generated. May Contain Errors. Read More Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HKMPY Stock News HeadlinesHikma Advances Epinephrine Nasal Spray With Multi-market Regulatory FilingsSeptember 11, 2026 | rttnews.comHikma Pharmaceuticals PLC ADR HKMPYAugust 15, 2026 | morningstar.comMDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 14 at 1:00 AM | Profits Run (Ad)Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comHikma comments on Supreme Court of the United States' unanimous decision in favour of HikmaJune 4, 2026 | prnewswire.comUS Supreme Court backs generic drugmaker in 'skinny label' patent caseJune 4, 2026 | reuters.comHikma Pharmaceuticals PLC (HKMPY) Sales/ Trading Statement Call TranscriptApril 23, 2026 | seekingalpha.comUK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran warApril 23, 2026 | reuters.comSee More Headlines HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed this year? Hikma Pharmaceuticals' stock was trading at $41.92 at the beginning of the year. Since then, HKMPY stock has increased by 0.3% and is now trading at $42.03. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:HKMPY CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,400Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio13.58 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:HKMPY) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
